Header

UZH-Logo

Maintenance Infos

Comparative in-vitro activity of fleroxacin and other 6-fluoroquinolones against mycobacteria


Salfinger, Max; Hohl, Peter; Kafader, Felicitas M (1988). Comparative in-vitro activity of fleroxacin and other 6-fluoroquinolones against mycobacteria. Journal of Antimicrobial Chemotherapy, 22(Supplement):55-63.

Abstract

The susceptibility of 11 clinical isolates of Mycobacterium tuberculosis, 3 M. kansasii,3 M. xenopi, 2 M.scrofulaceum, 2 M. marinum, 2 M. malmoense to fleroxacin,ciprofloxacin, norfloxacin, rifampicin, isoniazid, ethambutol, and streptomycin was determined by the standard proportion method (Middlebrook 7HlO agar). All M.tuberculosis,M. kansasii, M. xenopi,M. scrofulaceum, M. marinum,and M. malmoense isolates including those resistant to conventional antimycobacterials were inhibited by 0·5 mg/l of fleroxacin and ciprofloxacin, the lowest tested concentration. Fleroxacin and ciprofloxacin along with ofloxacin,pefloxacin, ansamycin, clofazimine and cycloserine were also tested against 14 isolates of the M. avium complex. Nine of 14 strains (64%) of the M. avium complex were found susceptible to 4 mg/l of fleroxacin and a similar percentage to the other quinolones. On the basis of its in-vitro potency and its favourable pharmacokinetic properties fleroxacin appears to be sufficiently active to warrantfurther experimental trials against difficult to treat mycobacteria

Abstract

The susceptibility of 11 clinical isolates of Mycobacterium tuberculosis, 3 M. kansasii,3 M. xenopi, 2 M.scrofulaceum, 2 M. marinum, 2 M. malmoense to fleroxacin,ciprofloxacin, norfloxacin, rifampicin, isoniazid, ethambutol, and streptomycin was determined by the standard proportion method (Middlebrook 7HlO agar). All M.tuberculosis,M. kansasii, M. xenopi,M. scrofulaceum, M. marinum,and M. malmoense isolates including those resistant to conventional antimycobacterials were inhibited by 0·5 mg/l of fleroxacin and ciprofloxacin, the lowest tested concentration. Fleroxacin and ciprofloxacin along with ofloxacin,pefloxacin, ansamycin, clofazimine and cycloserine were also tested against 14 isolates of the M. avium complex. Nine of 14 strains (64%) of the M. avium complex were found susceptible to 4 mg/l of fleroxacin and a similar percentage to the other quinolones. On the basis of its in-vitro potency and its favourable pharmacokinetic properties fleroxacin appears to be sufficiently active to warrantfurther experimental trials against difficult to treat mycobacteria

Statistics

Citations

Dimensions.ai Metrics
8 citations in Web of Science®
7 citations in Scopus®
Google Scholar™

Altmetrics

Downloads

16 downloads since deposited on 18 Oct 2018
10 downloads since 12 months
Detailed statistics

Additional indexing

Item Type:Journal Article, refereed, original work
Communities & Collections:National licences > 142-005
Dewey Decimal Classification:570 Life sciences; biology
610 Medicine & health
Scopus Subject Areas:Life Sciences > Pharmacology
Health Sciences > Microbiology (medical)
Health Sciences > Infectious Diseases
Health Sciences > Pharmacology (medical)
Language:English
Date:1 October 1988
Deposited On:18 Oct 2018 09:29
Last Modified:31 Jul 2020 02:17
Publisher:Oxford University Press
ISSN:0305-7453
OA Status:Green
Free access at:Publisher DOI. An embargo period may apply.
Publisher DOI:https://doi.org/10.1093/jac/22.supplement_d.55
Related URLs:https://www.swissbib.ch/Search/Results?lookfor=nationallicenceoxford101093jac22Supplement_D55 (Library Catalogue)

Download

Green Open Access

Download PDF  'Comparative in-vitro activity of fleroxacin and other 6-fluoroquinolones against mycobacteria'.
Preview
Content: Published Version
Language: English
Filetype: PDF (Nationallizenz 142-005)
Size: 692kB
View at publisher